Sudeep Pharma Limited (BOM:544619)
India · Delayed Price · Currency is INR 844.25
-5.55 (-0.65%)
At close: Jun 19, 2026
Sudeep Pharma Revenue
In the fiscal year ending March 31, 2026, Sudeep Pharma had annual revenue of 6.42B INR with 27.94% growth. Sudeep Pharma had revenue of 1.82B in the quarter ending March 31, 2026, with 15.74% growth.
Revenue
6.42B
Revenue Growth
+27.94%
P/S Ratio
14.62
Revenue / Employee
13.38M
Employees
740
Market Cap
93.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.42B | 1.40B | 27.94% |
| Mar 31, 2025 | 5.02B | 427.19M | 9.30% |
| Mar 31, 2024 | 4.59B | 305.42M | 7.12% |
| Mar 31, 2023 | 4.29B | 841.21M | 24.41% |
| Mar 31, 2022 | 3.45B | 3.38B | 4,999.06% |
| Mar 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 23.19B |
| Neuland Laboratories | 20.23B |
| Shilpa Medicare | 15.39B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 5.01B |
| Sai Parenteral's | 3.81B |
| Anlon Healthcare | 1.72B |
| Gujarat Themis Biosyn | 1.66B |